Attached herewith the press release for the audited financial results for March, 2026.
RESULTS
▲ Positive Development
MEDIUM RISK
📅 Filed on BSE: 02 Jun 2026, 05:14 PM IST · BSE ID: 44d00a68-26f8-42ea-9f57-52d56b8873c8
View Original BSE Filing (PDF)
💡
In Simple Terms
The company announced its annual financial results, showing significant growth in sales and profit for the past year.
🤖 AI Summary
- Veerhealth Care Limited reported Total Income of ₹33.29 Crore for FY26, an 86.08% YoY growth.
- EBITDA for FY26 stood at ₹3.27 Crore, reflecting an 82.68% YoY growth.
- Net Profit for FY26 increased by 38.16% YoY to ₹0.54 Crore, with a 1.62% Net Profit Margin.
- The company secured export orders worth ₹119 crore and domestic orders totaling ₹12.15 crore in FY26.
- Veerhealth Care is expanding e-commerce presence and commenced production at a new manufacturing facility.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Total Income
₹ 33.29 Crore
86.08%
EBITDA
₹ 3.27 Crore
82.68%
Net Profit
₹ 0.54 Crore
38.16%
USA Export Orders (FY26)
₹ 119 crs
Domestic Marketplace Orders (FY26)
₹ 0.28 crs
Domestic Pharmacy Chain Orders (FY26)
₹ 1.79 crs
Leading FMCG Company Orders (FY26)
₹ 10.08 crs
🏢 How This Affects the Company
The company's Total Income growth of 86.08% and specific order wins totaling ₹131.15 crore indicate expansion in both export and domestic market penetration, potentially strengthening its market position in Ayurveda and oral care.
The 82.68% YoY EBITDA growth and 38.16% YoY Net Profit growth for FY26 suggest improved operational efficiency and profitability. However, EBITDA Margin declined by 18 BPS and Net Profit Margin by 56 BPS.
Commencement of production at a new facility with in-house plastic molding demonstrates backward integration and increased manufacturing capacity, supporting 'Local to Global' ambitions. Onboarding Ayuveer products on Myntra expands e-commerce reach.
The Q4FY26 profit was impacted by Forex Loss of ₹0.31 Crore and a provision for Deferred Tax of ₹0.49 Crore. While the company does not expect a repeat of these specific expenses in FY27, foreign currency fluctuations remain a potential risk for export-oriented operations.
👥 What This Means For Shareholders
✅
Action Required
No action is required from shareholders based on this financial results disclosure.
👤
Who Is Affected
Shareholders are affected by the disclosed financial performance, including the 86.08% YoY increase in Total Income and 38.16% YoY Net Profit growth, which reflects the company's operational profitability for FY26.
🔍
Management Signal
Management is signaling a focus on international expansion, manufacturing capacity enhancement, and sustained high growth rates, supported by a strong order book.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Q1 FY27 results — monitor Total Revenues against FY27 expectations of ₹70-75 crore.
Updates on US market medical device exports and Russian oral care market entry.
Further details on USFDA plant clearance status and implications for global expansion.
MEDIUM RISK
While strong growth is present, margin compression and reliance on future export market entries pose financial and execution risks.
💡 Investor Takeaway
Veerhealth Care Limited reported Total Income of ₹33.29 Crore for FY26, an 86.08% YoY increase. EBITDA grew 82.68% to ₹3.27 Crore, and Net Profit rose 38.16% to ₹0.54 Crore. The company secured ₹119 crs in USA export orders during FY26.
⚖️ Strengths & Concerns
✅ Positives
- Total Income for FY26 grew by 86.08% YoY, reaching ₹33.29 Crore, reflecting substantial business expansion.
- Secured significant orders in FY26, including USA Exports of ₹119 crs, driving strong revenue generation.
⚠️ Concerns
- EBITDA Margin for FY26 declined by 18 BPS to 9.82%, indicating increased operational costs relative to revenue growth.
- Net Profit Margin for FY26 declined by 56 BPS to 1.62%, despite profit growth, impacted by exceptional items and deferred tax.
❓ Frequently Asked Questions
What was Veerhealth Care Limited's Total Income for FY26?
Veerhealth Care Limited reported a Total Income of ₹33.29 Crore for the financial year ended March 31, 2026, marking an 86.08% year-on-year growth.
How much did Veerhealth Care Limited's Net Profit increase in FY26?
Net Profit for Veerhealth Care Limited in FY26 was ₹0.54 Crore, an increase of 38.16% year-on-year.
What was Veerhealth Care Limited's EBITDA for FY26?
Veerhealth Care Limited's EBITDA for FY26 was ₹3.27 Crore, representing an 82.68% year-on-year growth.
What were the key orders received by Veerhealth Care Limited in FY26?
In FY26, Veerhealth Care Limited received orders including USA Exports of ₹119 crs, Domestic marketplace of ₹0.28 crs, Domestic pharmacy chain of ₹1.79 crs, and a Leading FMCG company of ₹10.08 crs.
What was the impact on Veerhealth Care Limited's Q4FY26 profit?
Veerhealth Care Limited's Q4FY26 profit was impacted by a Forex Loss of ₹0.31 Crore classified as an Exceptional item and a Provision for Deferred Tax of ₹0.49 Crore.
Questions based on this BSE filing only. For information purposes.